MiNK Therapeutics (INKT)
NASDAQ:INKT
Top Page
MiNK Therapeutics
(NASDAQ:INKT)
Select Model
Select Model
Rating:48Neutral
Price Target:
$12.50
▲(13.43% Upside)
Action:UpgradedDate:12/30/25
The score is primarily held down by weak financial fundamentals (pre-revenue, negative equity, and highly concerning TTM cash flow metrics). This is partially offset by a constructive earnings call centered on clinical progress and runway, while technicals and valuation provide limited additional support.
Positive Factors
Clinical efficacy of AGENT-797
Durable median overall survival (~23 months) and observed complete remissions in heavily pretreated patients provide lasting validation of the iNKT platform's potency across tumor types, improving the program's regulatory and partner-attraction prospects and reducing long-term clinical risk.
Negative Factors
Negative stockholders' equity
Persistent negative equity reflects accumulated losses and limits borrowing capacity, weakening financial flexibility. This structural balance-sheet weakness increases the likelihood of dilutive financings and constrains strategic options until profitability or a recapitalization restores equity.
Read all positive and negative factors
Positive Factors
Negative Factors
Clinical efficacy of AGENT-797
Durable median overall survival (~23 months) and observed complete remissions in heavily pretreated patients provide lasting validation of the iNKT platform's potency across tumor types, improving the program's regulatory and partner-attraction prospects and reducing long-term clinical risk.
Read all positive factors
MiNK Therapeutics (INKT) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$51.73M
Dividend YieldN/A
Average Volume (3M)39.56K
Price to Earnings (P/E)―
Beta (1Y)0.13
Revenue GrowthN/A
EPS Growth21.48%
CountryUS
Employees23
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.65
Shares Outstanding4,694,155
10 Day Avg. Volume31,712
30 Day Avg. Volume39,559
Financial Highlights & Ratios
PEG Ratio0.04
Price to Book (P/B)-1.33
Price to Sales (P/S)0.00
P/FCF Ratio-2.73
Enterprise Value/Market Cap0.83
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-219.10
Enterprise Value/Ebitda-3.55
Forecast
1Y Price Target
$35.00Price Target Upside217.60% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-3.61
Revenue Forecast (FY)N/A
MiNK Therapeutics Business Overview & Revenue Model
Company Description
MiNK Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-media...
How the Company Makes Money
MiNK Therapeutics makes money through the research and development of its iNKT cell therapies, which are primarily funded through a combination of private investments, public offerings, and strategic partnerships. The company generates revenue by ...
MiNK Therapeutics Earnings Call Summary
Earnings Call Date:Nov 14, 2025
(Q3-2025)
| % Change Since: |
Next Earnings Date:Mar 31, 2026
Earnings Call Sentiment Positive
The earnings call for MiNK Therapeutics was predominantly positive, highlighting significant clinical trial successes, strategic partnerships, and advancements in manufacturing capabilities. While there was an increase in net loss, the company's financial strategy and strong leadership suggest a positive outlook for future growth.Positive Updates
Successful Clinical Trials and Data
MiNK Therapeutics presented updated clinical data from their ongoing trial of AGENT-797, demonstrating a median overall survival of approximately 23 months in a refractory setting with patients who had heavily pretreated immune therapy-resistant solid tumors. Complete remission was observed in a patient with metastatic testicular cancer and durable partial response in second-line gastric cancer.
Negative Updates
Increased Net Loss
MiNK reported a net loss of $2.9 million for the quarter ended September 30, 2025, compared to $1.8 million in the previous year, indicating an increase in operational expenses.
Read all updates
Q3-2025 Updates
Positive
Negative
Successful Clinical Trials and Data
MiNK Therapeutics presented updated clinical data from their ongoing trial of AGENT-797, demonstrating a median overall survival of approximately 23 months in a refractory setting with patients who had heavily pretreated immune therapy-resistant solid tumors. Complete remission was observed in a patient with metastatic testicular cancer and durable partial response in second-line gastric cancer.
Read all positive updates
Company Guidance
During the third quarter 2025 conference call for MiNK Therapeutics, Inc., significant progress was discussed, especially concerning their INKT cell therapy platform. The updated clinical trial data for AGENT-797, used both alone and in combination with anti-PD-1 in patients with relapsed or refractory solid tumors, showed remarkable results, including a median overall survival of approximately 23 months, with some cases achieving complete remission. The therapy demonstrated durable responses across various cancer types and was noted for its lack of severe toxicities, with mild fatigue being the most common side effect. Financially, MiNK ended the quarter with a cash balance of $14.3 million, raising an additional $1.2 million through an at-the-market sales agreement. The net loss for the quarter was $2.9 million, reflecting an increase from the previous year due to ongoing support of AGENT-797 programs. Looking ahead, the company is preparing for a global Phase two trial in acute pulmonary dysfunction and advancing their graft-versus-host disease (GVHD) study, supported by public-private partnerships and federal grants.MiNK Therapeutics Financial Statement Overview
Summary
Income Statement
12
Very Negative
Balance Sheet
18
Very Negative
Cash Flow
8
Very Negative
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -197.05K | -215.44K | -204.62K | -121.75K | -77.96K | -55.06K |
| EBITDA | -12.16M | -10.57M | -22.25M | -27.87M | -27.70M | -13.74M |
| Net Income | -12.36M | -10.78M | -22.46M | -27.99M | -30.21M | -16.24M |
Balance Sheet | ||||||
| Total Assets | 14.96M | 5.72M | 4.55M | 21.47M | 40.24M | 4.56M |
| Cash, Cash Equivalents and Short-Term Investments | 14.28M | 4.58M | 3.37M | 19.64M | 38.89M | 2.69M |
| Total Debt | 5.73M | 4.92M | 0.00 | 0.00 | 0.00 | 43.82M |
| Total Liabilities | 28.48M | 25.31M | 22.61M | 21.87M | 16.47M | 58.43M |
| Stockholders Equity | -13.51M | -19.59M | -18.06M | -401.30K | 23.78M | -53.87M |
Cash Flow | ||||||
| Free Cash Flow | -1.35B | -9.56M | -15.84M | -19.12M | -13.08M | -8.43M |
| Operating Cash Flow | -1.35B | -9.56M | -15.76M | -18.87M | -12.83M | -8.34M |
| Investing Cash Flow | 0.00 | 0.00 | -73.56K | -250.05K | -248.98K | -95.21K |
| Financing Cash Flow | 14.12M | 10.82M | -407.17K | -155.60K | 49.26M | 11.11M |
MiNK Therapeutics Technical Analysis
Positive
11.02
Price Trends
11.02
Positive
11.52
Negative
13.03
Negative
Market Momentum
-0.42
Negative
55.10
Neutral
60.55
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For INKT, the sentiment is Positive. The current price of 11.02 is above the 20-day moving average (MA) of 10.16, above the 50-day MA of 11.02, and below the 200-day MA of 13.03, indicating a neutral trend. The MACD of -0.42 indicates Negative momentum. The RSI at 55.10 is Neutral, neither overbought nor oversold. The STOCH value of 60.55 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for INKT.
MiNK Therapeutics Risk Analysis
MiNK Therapeutics disclosed 76 risk factors in its most recent earnings report. MiNK Therapeutics reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
MiNK Therapeutics Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
57 Neutral | $133.88M | 1.57 | 25.12% | ― | ― | 814.20% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | $306.62M | -0.46 | 70.29% | ― | -7.55% | -13.09% | |
48 Neutral | $51.73M | -5.39 | ― | ― | ― | 21.48% | |
46 Neutral | $33.55M | -2.04 | -83.24% | ― | -100.00% | 55.10% | |
40 Underperform | $4.88M | -1.64 | -370.46% | ― | ― | 2.26% |
* Healthcare Sector Average
INKT
MiNK Therapeutics
11.02
2.38
27.55%
VERU
Veru
2.09
-2.81
-57.35%
ORMP
Oramed Pharm
3.31
1.32
65.91%
ARMP
Armata Pharmaceuticals
8.37
6.91
473.29%
QNCX
Quince Therapeutics
0.09
-1.24
-93.46%
MiNK Therapeutics Corporate Events
Executive/Board Changes
MiNK Therapeutics announces board resignation amid public appointment
Neutral
Jan 2, 2026
On December 29, 2025, Robert Kadlec, MD, resigned from the Board of Directors of MiNK Therapeutics, Inc., including all committee roles, following his acceptance of a senior public service appointment as Assistant Secretary of War for Nuclear Dete...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.